Physician profile
Jaime Schofield
NPI 1124204987
$7,544.11
in general payments reported to CMS, 2019-2025
64 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,286 · 2022: $1,457 · 2023: $1,483 · 2024: $1,638 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,549 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,549.16 |
| Education | $251.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $600.42 | 2021-2025 | |
| Janssen Biotech, INC. | $586.42 | 2021-2025 | Erleada, Imbruvica, Darzalex |
| Abbvie INC. | $387.55 | 2021-2025 | |
| Incyte Corporation | $380.31 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $358.57 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $349.00 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $298.46 | 2021-2025 | Calquence, Enhertu, Imfinzi |
| Eisai INC. | $289.93 | 2021-2025 | |
| Amgen INC. | $264.71 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Glaxosmithkline, LLC. | $244.43 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $232.96 | 2022-2025 | |
| Emd Serono, INC. | $203.20 | 2021-2024 | |
| Celgene Corporation | $200.89 | 2021-2025 | Reblozyl |
| Genmab U.S., INC. | $197.14 | 2021-2025 | Tivdak, Epkinly |
| Pfizer INC. | $177.36 | 2021-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Schofield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.